CVRx, Inc.
- Open
- 5.12
- Day high
- 5.29
- Day low
- 5.03
- Prev close
- 5.14
- Volume
- 64K
- Mkt cap
- $139M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 4.8
- P/S
- 2.3
- Yield
- —
- Per share
- —
CVRx, Inc. (CVRX) is a Healthcare company listed on NASDAQ. The stock is down 15% over the past year.
CVRx, Inc. (CVRX) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
CVRX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 11, 2026 | $-0.51 | $-0.50 | +2.0% | $15M | +1.9% |
| Feb 12, 2026 | $-0.42 | $-0.46 | -9.5% | $16M | +14.0% |
| Nov 5, 2025 | $-0.50 | $-0.49 | +2.0% | $15M | -6.7% |
| May 8, 2025 | $-0.56 | $-0.53 | +5.4% | $12M | -7.3% |
| Feb 4, 2025 | $-0.37 | $-0.43 | -16.2% | $15M | +0.8% |
| Apr 30, 2024 | $-0.53 | $-1.04 | -96.2% | $11M | -5.7% |
| Jan 25, 2024 | $-0.55 | $-0.44 | +20.0% | $11M | +1.5% |
| Oct 26, 2023 | $-0.57 | $-0.43 | +24.6% | $11M | +7.0% |
| Jul 25, 2023 | $-0.57 | $-0.56 | +1.8% | $10M | -3.3% |
| Apr 27, 2023 | $-0.57 | $-0.55 | +3.5% | $8M | -6.9% |
| Jan 26, 2023 | $-0.55 | $-0.51 | +7.3% | $7M | -0.3% |
| Nov 1, 2022 | $-0.56 | $-0.48 | +14.3% | $6M | +8.1% |
CVRX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 3, 2026 | SLATTERY JOSEPH Pdirector | Grant | 11,182 | $5.43 |
| Jun 3, 2026 | Hill, Mitch C.director | Grant | 11,182 | $5.43 |
| Jun 3, 2026 | Hill, Mitch C.director | Grant | 8,720 | — |
| Jun 3, 2026 | Ballinger Kevin J.director | Grant | 8,720 | — |
| Jun 3, 2026 | Ballinger Kevin J.director | Grant | 11,182 | $5.43 |
| Jun 3, 2026 | SHADAN MARTHAdirector | Grant | 8,720 | — |
| Jun 3, 2026 | SHADAN MARTHAdirector | Grant | 11,182 | $5.43 |
| Jun 3, 2026 | DALE MICHAEL Ddirector | Grant | 29,005 | — |
| Jun 3, 2026 | DALE MICHAEL Ddirector | Grant | 36,252 | $5.43 |
| Jun 3, 2026 | Nielsen Kirk G.director | Grant | 8,720 | — |
| Jun 3, 2026 | Nielsen Kirk G.director | Grant | 11,182 | $5.43 |
| Jun 3, 2026 | Jain Mudit K.director | Grant | 8,720 | — |
| Jun 3, 2026 | Jain Mudit K.director | Grant | 11,182 | $5.43 |
| Jun 3, 2026 | SLATTERY JOSEPH Pdirector | Grant | 8,720 | — |
| Mar 16, 2026 | Adamson Philip B.officer: Chief Medical Officer | Grant | 41,000 | — |
Source: CVRX SEC Form 4 filings, latest Jun 3, 2026. For informational purposes only — not investment advice.
See the full CVRX insider & 13F page →CVRx, Inc. company profile
Overview
CVRx, Inc. (NASDAQ:CVRX) is a commercial-stage medical device company founded in 2000 and headquartered in Minneapolis, Minnesota. The company went public in June 2021 and specializes in developing neuromodulation solutions for cardiovascular diseases. CVRx has established itself as a pioneer in the emerging field of cardiovascular neuromodulation, focusing primarily on treating heart failure through its flagship Barostim device. After more than two decades of development and clinical testing, the company has successfully commercialized its technology and is actively expanding its market presence in the United States and Europe.
Business
CVRx operates in the cardiovascular medical device industry, specifically within the neuromodulation sector. The company's core product is Barostim, a neuromodulation device that represents a novel approach to treating heart failure. Heart failure is a chronic condition where the heart cannot pump blood effectively, affecting millions of patients worldwide and representing a significant healthcare burden. Barostim works by stimulating the carotid baroreceptors, which are natural sensors in the neck that help regulate blood pressure and heart rate. The device consists of an implantable pulse generator (similar to a pacemaker) and a lead that delivers electrical stimulation to these receptors. This stimulation activates the body's natural cardiovascular regulation system, helping to improve heart function and reduce symptoms in patients with heart failure with reduced ejection fraction (also called systolic heart failure). The company operates primarily as a single-segment business focused on heart failure treatment, with approximately 95% of revenue coming from U.S. operations and the remaining 5% from European markets, primarily Germany. CVRx has recently expanded its addressable market through FDA approval for broader patient populations, increasing its total addressable market to $2.2 billion annually in the United States alone.
Revenue model
CVRx generates revenue through direct product sales of its Barostim system to hospitals and medical centers. The company sells complete systems that include both the implantable pulse generator and the stimulation lead, with an average selling price of approximately $31,000 per unit. Revenue is recognized when the device is implanted in patients, creating a direct correlation between patient treatments and company income. The company's business model depends heavily on hospital reimbursement from government and private insurance payers. CVRx has secured favorable reimbursement rates, with hospitals receiving approximately $43,000 for inpatient procedures and $45,000 for outpatient procedures under current Medicare payment systems. This reimbursement structure creates positive economics for hospitals, as they receive more in reimbursement than they pay for the device. Several factors significantly impact CVRx's margins and growth potential. Positive factors include successful reimbursement advocacy that has increased payment rates, growing clinical evidence supporting the therapy's effectiveness, and an aging population with increasing heart failure prevalence. The company benefits from having secured new Category 1 CPT codes effective 2026, which should reduce prior authorization barriers and improve payment predictability. However, margin pressures come from the need for extensive sales force expansion, ongoing clinical trial costs, and regulatory compliance expenses. The company faces reimbursement uncertainty as payers periodically review coverage policies. Additionally, the therapy requires specialized physician training and patient education, creating adoption barriers that necessitate significant marketing and education investments. Competition from alternative heart failure treatments and the need for continuous clinical evidence generation also impact profitability timelines.
Competitive moat
CVRx possesses a moderate but meaningful competitive moat built primarily around its pioneering position in cardiovascular neuromodulation and regulatory barriers to entry. The company holds the first and only FDA-approved device for baroreflex activation therapy in heart failure, providing significant first-mover advantages in an emerging therapeutic category. This regulatory approval represents years of clinical development and substantial investment that competitors would need to replicate. The company's moat is strengthened by its growing clinical evidence base, established relationships with key opinion leaders in cardiology, and increasingly favorable reimbursement landscape that it helped create through advocacy efforts. CVRx has built specialized expertise in navigating the complex regulatory and reimbursement environment for novel cardiovascular devices, creating institutional knowledge that would be difficult for new entrants to quickly replicate. However, the moat faces several vulnerabilities. The cardiovascular device market attracts well-funded competitors including large medical device companies like Medtronic, Abbott, and Boston Scientific, which have significantly greater resources and established physician relationships. These companies could potentially develop competing neuromodulation technologies or acquire smaller competitors. Additionally, alternative heart failure treatments continue to evolve, including new pharmaceutical therapies and other device-based interventions that could limit Barostim's market opportunity. The company's competitive position also depends on maintaining favorable reimbursement, which requires ongoing advocacy and clinical evidence generation. If reimbursement policies change unfavorably or if clinical evidence emerges questioning the therapy's cost-effectiveness, the moat could erode quickly. The relatively small size of CVRx compared to major cardiovascular device companies also limits its ability to invest in multiple product lines or geographic expansion simultaneously.
Risks & safety
CVRx demonstrates a strong margin of safety from a balance sheet perspective but faces ongoing profitability challenges that create cash burn concerns. • **Liquidity Position**: Strong with $102.7 million in cash and short-term investments as of Q1 2025, providing substantial runway for operations • **Debt Level**: Moderate debt-to-equity ratio of 0.72, manageable given the company's cash position and growth trajectory • **Cash Burn**: Significant with quarterly operating cash flow of -$12.8 million in Q1 2025, though this represents investment in growth rather than distress • **Current Ratio**: Excellent at 14.8, indicating very strong short-term liquidity • **Valuation Metrics**: Trading at reasonable multiples given growth profile - P/E of -5.7 (based on losses), EV/EBITDA of -4.9 • **Revenue Growth**: Consistent growth trajectory with 15% year-over-year increase in Q1 2025 • **Market Position**: Established reimbursement and growing clinical adoption provide revenue visibility • **Regulatory Risk**: Mitigated by existing FDA approvals and established reimbursement codes
Recent development
Over the past few years, CVRx has executed several strategic initiatives to strengthen its market position and accelerate growth. The company achieved a major milestone with the successful completion of its BeAT-HF clinical trial, which led to FDA approval for expanded labeling in December 2023. This approval significantly increased the company's total addressable market from previous estimates to $2.2 billion annually, encompassing approximately 76,000 new patients per year in the United States. CVRx has substantially strengthened its commercial infrastructure, expanding from 14 U.S. sales territories in 2021 to 42 territories by 2024. The company has also invested heavily in leadership talent, bringing in experienced executives including Robert John as Chief Revenue Officer, Dr. Philip Adamson as Chief Medical Officer, and other key positions focused on patient access and clinical research. These hires represent a strategic shift toward building a more sophisticated commercial organization capable of deeper market penetration. The company has made significant progress on reimbursement, securing increased inpatient DRG payments from $23,000 to $43,000 and maintaining favorable outpatient reimbursement of $45,000. Most importantly, CVRx obtained new Category 1 CPT codes effective January 2026, which should reduce prior authorization barriers and improve payment predictability for providers. Recent strategic pivots include a more targeted approach to market development, focusing on high-potential centers with large heart failure patient volumes rather than rapid expansion to numerous smaller accounts. The company has also launched comprehensive physician education programs, including the ASCEND Heart Failure Fellows program, and is exploring potential pragmatic randomized controlled trials to generate additional real-world evidence supporting the therapy's cost-effectiveness.
CVRX company profile · for informational purposes only — not investment advice.
Track CVRX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free